Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections

References

• Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-32
   PubMedGoogle Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edama. Ophthalmology 1984;91:1464-74
   PubMed Web of Science ®Google Scholar
• Klein R, Moss SE, Klein BE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XI: the incidence of macular edema. Ophthalmology 1989;96:1501-2
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2
   PubMed Web of Science ®Google Scholar
• Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008;30:65-84
   PubMed Web of Science ®Google Scholar
• Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-9
   PubMed Web of Science ®Google Scholar
• Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90
   PubMed Web of Science ®Google Scholar
• Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005
   PubMed Web of Science ®Google Scholar
• Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-7
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest ophthalmol Vis Sci 2003;44:2155-62
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7
   PubMed Web of Science ®Google Scholar
• Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9
   PubMed Web of Science ®Google Scholar
• The diabetes control and complications trial research group: the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research group. Photocoagulation for diabetic macular edama: Early Treatment Diabetic Retinopaty Study report number 1. Arch Ophthalmol 1995;113(9):1144-55
   Google Scholar
• Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long term visual results. Ophthalmology 1991;98:1594-602
   PubMed Web of Science ®Google Scholar
• Harbour JM, Smiddy WE Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996;121:405-13
   PubMed Web of Science ®Google Scholar
• Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophtalmol 2000;130:178-86
   PubMed Web of Science ®Google Scholar
• Jonas JB, Söfker A. Intraocular injection of cristalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7
   PubMed Web of Science ®Google Scholar
• Schalts H, Madeira D, Mc Donald R, Johnson RN. Progressive enlargement of laser scars following grid lazer photocoagulation for diffuse diabetic macular edema. Arch Ophtalmol 1991;109:1549-51
   Google Scholar
• Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992;113:652-6
   PubMed Web of Science ®Google Scholar
• Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-58
   PubMed Web of Science ®Google Scholar
• Karaçorlu M, Ozdemir H, Senturk F, et al. Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema. Acta Ophthalmol 2010;88(5):558-63
   Google Scholar
• Ornek K, Ornek N. Intravitreal bevacizumab treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2008;24(4):403-7
   Google Scholar
• Astam N, Batioğlu F, Ozmert E. Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmology 2009;29(5):343-8
   Google Scholar
• Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28(8):1053-60
   Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 study group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117(11):2146-51
   PubMed Web of Science ®Google Scholar
• Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156(3):502-10
   Google Scholar
• Ford JA, Elders A, Shyangdan D, et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 2012;345:5182
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5):536-44
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114(5):5-859
   Google Scholar
• Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27(9):1260-6
   PubMed Web of Science ®Google Scholar